Our portfolio

CEPI is working to end pandemics by supporting the research and development of a diverse portfolio of vaccine candidates based on a range of vaccine approaches.

Explore our portfolio

CEPI funds the development of vaccine candidates against our priority pathogens and vaccine platforms to enable rapid development of vaccines against Disease X. Our interactive portfolio provides information on each of the vaccine candidates that CEPI has invested in as well as our Centralised Lab Network and Vaccine Manufacturing Network partners. Additional CEPI-funded partnerships will be added in the coming months to provide a full overview of all of CEPI’s investments. Filter information by developer, disease, phase of development, or vaccine type. You can also download a summary of our active portfolio.

Active portfolio summary

Portfolio: list view

Filter the portfolio
Disease
Partner type
Partners
Phase
Vaccine type

Affinivax

Broadly Protective Coronavirus Vaccine

Affinivax - Broadly Protective Coronavirus Vaccine
Vaccine Developer
Vaccine type:
Multiple Antigen Presenting System technology
Funding:
Up to $4.5 million

CEPI supported the development of a vaccine candidate based on Affinivax’s innovative Multiple Antigen Presenting System (MAPSTM) technology.

The programme aimed to establish preclinical proof of concept for a vaccine candidate designed to protect against new COVID-19 variants suitable for use in the Global South.

CEPI funding has been discontinued.

Phase
  • Funding Discontinued
Tags
  • Multiple Antigen Presenting System technology
  • Coronavirus
  • Broadly protective coronavirus vaccine
  • COVID-19 variants

Akagera Medicines

Disease X

Akagera - Disease X
Vaccine Developer
Vaccine type:
Nucleic Acid
Funding:
Up to $1.5 million

CEPI is providing up to US $1.5 million to Akagera Medicines to demonstrate the pre-clinical proof of concept of their lipid nanoparticles (LNPs) and modified mRNA for the development of a multivalent influenza vaccine.

Their LNP formulation could optimise delivery of mRNA and reduce potential LNP-associated adverse events.

The technology could also improve the stability of the mRNA-based vaccines, removing the need for frozen storage to bolster equitable vaccine access.

Benefits could also include enhanced shelf life, reduced Cost of Goods, and a reduction in the required effective dose which would extend the number of doses that could be produced.

Phase
  • Preclinical
Tags
  • Disease X
  • MRNA

Amplitude Therapeutics

Disease X

Amplitude Therapeutics - Disease X
Vaccine Developer
Vaccine type:
Trans-amplifying mRNA
Funding:
Up to $1 million

Researchers at Amplitude Therapeutics will perform preclinical studies that assess whether their trans-amplifying mRNA vaccine approach could provide a simplified alternative to the self-amplifying mRNA vaccine technique being used today.

Trans-amplifying mRNA vaccines consist of two separate, short RNA fragments - one encoding the antigen and one encoding the replicase.

By separating out the target antigen and replicase sequences, the vaccine could be more easily produced in vaccine manufacturing facilities. Compared to conventional mRNA vaccines, the design could also mean up to 100 times less antigen-encoded RNA is needed per dose and the replicase enzyme can be produced ahead of an outbreak as it does not need to be combined with the target antigen sequence.

Phase
  • Preclinical
Tags
  • MRNA
  • Disease X

Aspen Pharmacare

Aspen - Manufacturing
Manufacturing Partner
Funding:
Up to $30 million

Aspen is one of CEPI’s vaccine manufacturing network members. The network aims to substantially increase the world’s capacity and capability to produce vaccines against emerging outbreaks in as little as 100 days.

In December 2022, CEPI and the Bill and Melinda Gates Foundation partnered with Aspen Pharmacare in South Africa. Both CEPI and the Gates Foundation are providing up to $15 million to support a ten-year agreement between Aspen and Serum Institute India to expand the supply and sourcing of affordable vaccines manufactured in Africa.

Through the partnership with Serum, Aspen will manufacture and distribute four routine vaccines—Pneumococcal, Rotavirus, Polyvalent Meningococcal, and Hexavalent—in Africa. The funding from CEPI and the Gates Foundation will also help sustain regional vaccine manufacturing capacity at Aspen for potential future outbreak response, with the intention of securing early access to African-produced vaccines in the event of a future public health emergency.

Tags
  • Manufacturing

Auro vaccines & PATH

Nipah

Auro Vaccines - Nipah
Vaccine Developer
Vaccine type:
HeV-sG-V vaccine
Funding:
Up to $25 million

CEPI is providing up to US $25 million to advance development of the Nipah virus vaccine candidate, HeV-Sg-V.

HeV-sG-V Nipah is a recombinant subunit vaccine that contains a portion of the G glycoprotein of Hendra virus, a henipavirus closely related to Nipah.

HeV-sG-V became the first-ever Nipah vaccine candidate to enter in-human testing in 2020. The trial, sponsored by Auro Vaccines, investigated the safety, tolerability, and immunogenicity of the vaccine candidate.

PATH is leading clinical operations and CEPI is funding the programme through Phase 2 clinical trials. Under the terms of the original agreement awarded by CEPI, Emergent BioSolutions has provided contract development and manufacturing services to produce the Phase 1 clinical trial material. Through a separate agreement with Auro Vaccines, Emergent has an exclusive option to license and assume control of development activities for the Nipah virus vaccine candidate.

Phase
  • Phase 1
Tags
  • HeV-sG-V vaccine
  • Nipah
Changed to page 1 of 21
1 of 21